Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
04 2019
Historique:
received: 19 03 2018
accepted: 22 10 2018
pubmed: 7 12 2018
medline: 30 5 2020
entrez: 7 12 2018
Statut: ppublish

Résumé

Systemic inflammation (SI) is involved in the pathogenesis of acute decompensation (AD) and acute-on-chronic liver failure (ACLF) in cirrhosis. In other diseases, SI activates tryptophan (Trp) degradation through the kynurenine pathway (KP), giving rise to metabolites that contribute to multiorgan/system damage and immunosuppression. In the current study, we aimed to characterize the KP in patients with cirrhosis, in whom this pathway is poorly known. The serum levels of Trp, key KP metabolites (kynurenine and kynurenic and quinolinic acids), and cytokines (SI markers) were measured at enrollment in 40 healthy subjects, 39 patients with compensated cirrhosis, 342 with AD (no ACLF) and 180 with ACLF, and repeated in 258 patients during the 28-day follow-up. Urine KP metabolites were measured in 50 patients with ACLF. Serum KP activity was normal in compensated cirrhosis, increased in AD and further increased in ACLF, in parallel with SI; it was remarkably higher in ACLF with kidney failure than in ACLF without kidney failure in the absence of differences in urine KP activity and fractional excretion of KP metabolites. The short-term course of AD and ACLF (worsening, improvement, stable) correlated closely with follow-up changes in serum KP activity. Among patients with AD at enrollment, those with the highest baseline KP activity developed ACLF during follow-up. Among patients who had ACLF at enrollment, those with immune suppression and the highest KP activity, both at baseline, developed nosocomial infections during follow-up. Finally, higher baseline KP activity independently predicted mortality in patients with AD and ACLF. Conclusion: Features of KP activation appear in patients with AD, culminate in patients with ACLF, and may be involved in the pathogenesis of ACLF, clinical course, and mortality.

Identifiants

pubmed: 30521097
doi: 10.1002/hep.30363
doi:

Substances chimiques

Kynurenine 343-65-7
Tryptophan 8DUH1N11BX

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1686-1701

Subventions

Organisme : European Foundation for the Study of Chronic Liver Failure (EF-Clif)
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2018 by the American Association for the Study of Liver Diseases.

Auteurs

Joan Clària (J)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.
Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.

Richard Moreau (R)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.
Inserm, Centre de Recherche sur l'Inflammation, Université Paris Diderot-Paris, Département Hospitalo-Universitaire UNITY; Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris; Laboratoire d'Excellence Inflamex, ComUE Sorbonne Paris Cité, Paris, France.

François Fenaille (F)

CEA, INRA, Université Paris Saclay, Laboratoire d'Etude du Métabolisme des Médicaments, MetaboHUB-Paris, Gif-Sur-Yvette, France.

Alex Amorós (A)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.

Christophe Junot (C)

CEA, INRA, Université Paris Saclay, Laboratoire d'Etude du Métabolisme des Médicaments, MetaboHUB-Paris, Gif-Sur-Yvette, France.

Henning Gronbaek (H)

Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.

Minneke J Coenraad (MJ)

Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.

Alain Pruvost (A)

CEA, INRA Université Paris Saclay, Service de Pharmacologie et Immunoanalyse, Plateforme SMArt-MS, Gif-sur-Yvette, France.

Aurélie Ghettas (A)

CEA, INRA Université Paris Saclay, Service de Pharmacologie et Immunoanalyse, Plateforme SMArt-MS, Gif-sur-Yvette, France.

Emeline Chu-Van (E)

CEA, INRA, Université Paris Saclay, Laboratoire d'Etude du Métabolisme des Médicaments, MetaboHUB-Paris, Gif-Sur-Yvette, France.

Cristina López-Vicario (C)

Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.

Karl Oettl (K)

Medical University of Graz, Graz, Austria.

Paolo Caraceni (P)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Carlo Alessandria (C)

Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Torino, Italy.

Jonel Trebicka (J)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.
Department of Internal Medicine I, University of Bonn, Bonn, Germany.
J.W. Goethe University Hospital, Frankfurt, Germany.

Marco Pavesi (M)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.

Carme Deulofeu (C)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.

Agustin Albillos (A)

Hospital Ramón y Cajal, Madrid, Spain.

Thierry Gustot (T)

CUB Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Tania M Welzel (TM)

J.W. Goethe University Hospital, Frankfurt, Germany.

Javier Fernández (J)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.
Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.

Rudolf E Stauber (RE)

Medical University of Graz, Graz, Austria.

Faouzi Saliba (F)

Hôpital Paul Brousse, Université Paris-Sud, Villejuif, France.

Noémie Butin (N)

CEA, INRA, Université Paris Saclay, Laboratoire d'Etude du Métabolisme des Médicaments, MetaboHUB-Paris, Gif-Sur-Yvette, France.

Benoit Colsch (B)

CEA, INRA, Université Paris Saclay, Laboratoire d'Etude du Métabolisme des Médicaments, MetaboHUB-Paris, Gif-Sur-Yvette, France.

Christophe Moreno (C)

CUB Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

François Durand (F)

Inserm, Centre de Recherche sur l'Inflammation, Université Paris Diderot-Paris, Département Hospitalo-Universitaire UNITY; Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris; Laboratoire d'Excellence Inflamex, ComUE Sorbonne Paris Cité, Paris, France.

Frederik Nevens (F)

University Hospital Gasthuisberg, KU Leuven, Belgium.

Rafael Bañares (R)

Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Daniel Benten (D)

University Hospital Hamburg-Eppendorf, Germany.

Pere Ginès (P)

Hospital Clínic, IDIBAPS and CIBERehd, Barcelona, Spain.

Alexander Gerbes (A)

Department of Medicine II, University Hospital LMU Munich, Liver Center Munich, Munich, Germany.

Rajiv Jalan (R)

Liver Failure Group, Institute for Liver Disease Health, University College London, Royal Free Hospital, London, United Kingdom.

Paolo Angeli (P)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.
Unit of Internal Medicine and Hepatology, Department of Medicine, DIMED, University of Padova, Padoa, Italy.

Mauro Bernardi (M)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Vicente Arroyo (V)

European Foundation for the Study of Chronic Liver Failure Consortium and Grifols Chair, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH